Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released for quarter ended June 30, 2026.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Full financial results and management commentary contained in Exhibit 99.1 press release
- Results furnished under Regulation FD, limiting Section 18 liability and automatic incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $50.2M, or $0.90/share, versus $31.6M, reflecting sharply higher development spending
- R&D expense $48.7M, up from $26.3M, as Phase 2 and Phase 3 claseprubart programs accelerate
- Approximately $1.2B cash and investments supports projected operations into 2030, reducing near-term financing risk
- CAPTIVATE interim analysis showed 75% response among first 40 CIDP participants versus 50% target, supporting claseprubart’s lead asset thesis
- Key catalysts: MMN top-line results December 2026, CAPTIVATE Part B guidance by year-end 2026, and gMG results expected 2H 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.